12:00 AM
May 10, 2010
 |  BC Week In Review  |  Company News  |  Deals

Artes Biotechnology, Q Chip deal

The companies partnered to develop monthly sustained-release formulations of interferon alpha 2a to treat HCV and HBV....

Read the full 64 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >